Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

ERS/EAACI statement on severe exacerbations in asthma in adults: facts, priorities and key research questions.

Bourdin A, Bjermer L, Brightling C, Brusselle GG, Chanez P, Chung KF, Custovic A, Diamant Z, Diver S, Djukanovic R, Hamerlijnck D, Horváth I, Johnston SL, Kanniess F, Papadopoulos N, Papi A, Russell RJ, Ryan D, Samitas K, Tonia T, Zervas E, Gaga M.

Eur Respir J. 2019 Sep 28;54(3). pii: 1900900. doi: 10.1183/13993003.00900-2019. Print 2019 Sep.

PMID:
31467120
2.

[Efficacy of Disease Management Programs Asthma and COPD? Results of a Cross-Sectional Study].

Kanniess F, Krockenberger K, Oepen P, Hedrich R, Olbrich D, Hessler N, Ziegler A, Langer-Brauburger B.

Dtsch Med Wochenschr. 2019 Jan;144(2):e1. doi: 10.1055/a-0837-2602. Epub 2019 Jan 23. German. No abstract available.

PMID:
30674053
3.

[Efficacy of Disease Management Programs Asthma and COPD? Results of a Cross-Sectional Study].

Kanniess F, Krockenberger K, Oepen P, Hedrich R, Olbrich D, Hessler N, Ziegler A, Langer-Brauburger B.

Dtsch Med Wochenschr. 2019 Jan;144(2):e12-e20. doi: 10.1055/a-0672-2461. Epub 2018 Nov 14. German. Erratum in: Dtsch Med Wochenschr. 2019 Jan;144(2):e1.

PMID:
30428493
4.

Patient Satisfaction and Clinical Outcomes with Budesonide plus Formoterol Spiromax for Asthma and Chronic Obstructive Pulmonary Disease: A Real-World, Observational Trial.

Gillissen A, Gessner C, Hechenbichler K, Herth FJF, Juenemann R, Kanniess F, Kardos P, Lommatzsch M, Schneidereit R, Windisch W.

Respiration. 2019;97(4):292-301. doi: 10.1159/000493860. Epub 2018 Nov 2.

PMID:
30391944
5.

Real-life effectiveness of asthma treatment with a fixed-dose fluticasone/formoterol pressurised metered-dose inhaler - Results from a non-interventional study.

Schmidt O, Petro W, Hoheisel G, Kanniess F, Oepen P, Langer-Brauburger B.

Respir Med. 2017 Oct;131:166-174. doi: 10.1016/j.rmed.2017.08.017. Epub 2017 Aug 19.

PMID:
28947024
6.

Effects of low- versus high-dose fluticasone propionate/formoterol fumarate combination therapy on AMP challenge in asthmatic patients: A double-blind, randomised clinical trial.

Kanniess F, Diamant Z, Lomax M.

Pulm Pharmacol Ther. 2016 Apr;37:65-72. doi: 10.1016/j.pupt.2016.02.003. Epub 2016 Feb 19.

PMID:
26912209
7.

Clinical asthma phenotypes in the real world: opportunities and challenges.

Bostantzoglou C, Delimpoura V, Samitas K, Zervas E, Kanniess F, Gaga M.

Breathe (Sheff). 2015 Sep;11(3):186-93. doi: 10.1183/20734735.008115. Review.

8.

Roflumilast for asthma: Efficacy findings in mechanism of action studies.

Bardin P, Kanniess F, Gauvreau G, Bredenbröker D, Rabe KF.

Pulm Pharmacol Ther. 2015 Dec;35 Suppl:S4-10. doi: 10.1016/j.pupt.2015.08.006. Epub 2015 Aug 19.

PMID:
26296794
9.

CXCR2 Antagonist MK-7123. A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease.

Rennard SI, Dale DC, Donohue JF, Kanniess F, Magnussen H, Sutherland ER, Watz H, Lu S, Stryszak P, Rosenberg E, Staudinger H.

Am J Respir Crit Care Med. 2015 May 1;191(9):1001-11. doi: 10.1164/rccm.201405-0992OC.

PMID:
25695403
10.

Longitudinal measurement of airway inflammation over one year in children and adults with intermittent asthma.

Pedersen F, Holz O, Kanniess F, Zielen S, Schulze J, Gillissen A, von Berg A, Berdel D, Beier J, Beeh K, Schnoor M, Magnussen H.

BMC Res Notes. 2014 Dec 17;7:925. doi: 10.1186/1756-0500-7-925.

11.

Extrafine beclomethasone/formoterol combination via a dry powder inhaler (NEXThaler(®)) or pMDI and beclomethasone monotherapy for maintenance of asthma control in adult patients: A randomised, double-blind trial.

Kanniess F, Scuri M, Vezzoli S, Francisco C, Petruzzelli S.

Pulm Pharmacol Ther. 2015 Feb;30:121-7. doi: 10.1016/j.pupt.2014.07.006. Epub 2014 Aug 1.

12.

Detection of exacerbations in asthma based on electronic diary data: results from the 1-year prospective BIOAIR study.

Kupczyk M, Haque S, Sterk PJ, Niżankowska-Mogilnicka E, Papi A, Bel EH, Chanez P, Dahlén B, Gaga M, Gjomarkaj M, Howarth PH, Johnston SL, Joos GF, Kanniess F, Tzortzaki E, James A, Middelveld RJ, Dahlén SE; BIOAIR investigators.

Thorax. 2013 Jul;68(7):611-8. doi: 10.1136/thoraxjnl-2012-201815. Epub 2013 Apr 6.

PMID:
23564399
13.

The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma.

Beeh KM, Kanniess F, Wagner F, Schilder C, Naudts I, Hammann-Haenni A, Willers J, Stocker H, Mueller P, Bachmann MF, Renner WA.

J Allergy Clin Immunol. 2013 Mar;131(3):866-74. doi: 10.1016/j.jaci.2012.12.1561. Epub 2013 Feb 4.

PMID:
23384679
14.

Airway response to emotional stimuli in asthma: the role of the cholinergic pathway.

Ritz T, Kullowatz A, Goldman MD, Smith HJ, Kanniess F, Dahme B, Magnussen H.

J Appl Physiol (1985). 2010 Jun;108(6):1542-9. doi: 10.1152/japplphysiol.00818.2009. Epub 2010 Apr 1.

15.

Emotional reactivity of the airways in asthma: consistency across emotion-induction techniques and emotional qualities.

Ritz T, Kullowatz A, Goldman MD, Kanniess F, Magnussen H, Dahme B.

Biol Psychol. 2010 Apr;84(1):74-81. doi: 10.1016/j.biopsycho.2010.02.016. Epub 2010 Mar 6.

PMID:
20211222
16.

[Efficacy and safety of a beta2-agonist-combination in patients with bronchial asthma--a clinical practice surveillance study].

Kanniess F.

MMW Fortschr Med. 2010 Jan 14;151 Suppl 4:188-92. German. No abstract available.

PMID:
21595147
17.

Bronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patients.

Joos GF, Schelfhout VJ, Pauwels RA, Kanniess F, Magnussen H, Lamarca R, Jansat JM, Garcia Gil E.

Respir Med. 2010 Jun;104(6):865-72. doi: 10.1016/j.rmed.2009.12.003. Epub 2009 Dec 30.

18.

Similar efficacy of ciclesonide versus prednisolone to treat asthma worsening after steroid tapering.

van den Berge M, Arshad SH, Ind PW, Magnussen H, Hamelmann E, Kanniess F, Postma DS.

Respir Med. 2009 Aug;103(8):1216-23. doi: 10.1016/j.rmed.2009.01.024. Epub 2009 Mar 18.

19.

Efficacy and safety of indacaterol, a new 24-hour beta2-agonist, in patients with asthma: a dose-ranging study.

Kanniess F, Boulet LP, Pierzchala W, Cameron R, Owen R, Higgins M.

J Asthma. 2008 Dec;45(10):887-92. doi: 10.1080/02770900802348321.

PMID:
19085578
20.

Psychological triggers and hyperventilation symptoms in asthma.

Ritz T, Kullowatz A, Bobb C, Dahme B, Magnussen H, Kanniess F, Steptoe A.

Ann Allergy Asthma Immunol. 2008 May;100(5):426-32. doi: 10.1016/S1081-1206(10)60466-8.

PMID:
18517073
21.

Stress effects on lung function in asthma are mediated by changes in airway inflammation.

Kullowatz A, Rosenfield D, Dahme B, Magnussen H, Kanniess F, Ritz T.

Psychosom Med. 2008 May;70(4):468-75. doi: 10.1097/PSY.0b013e31816f9c2f.

PMID:
18480192
22.

Perceived triggers of asthma: evaluation of a German version of the Asthma Trigger Inventory.

Ritz T, Kullowatz A, Kanniess F, Dahme B, Magnussen H.

Respir Med. 2008 Mar;102(3):390-8. Epub 2007 Dec 3.

23.

[New pharmacological options in the therapy of COPD].

Watz H, Kanniess F, Magnussen H.

Pneumologie. 2007 Jun;61(6):365-73. Epub 2007 May 10. Review. German.

PMID:
17492578
24.

Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study.

Sebastian M, Passlick B, Friccius-Quecke H, Jäger M, Lindhofer H, Kanniess F, Wiewrodt R, Thiel E, Buhl R, Schmittel A.

Cancer Immunol Immunother. 2007 Oct;56(10):1637-44. Epub 2007 Apr 5.

PMID:
17410361
25.

Indacaterol, a novel inhaled beta2-agonist, provides sustained 24-h bronchodilation in asthma.

Beeh KM, Derom E, Kanniess F, Cameron R, Higgins M, van As A.

Eur Respir J. 2007 May;29(5):871-8. Epub 2007 Jan 24.

26.

The influence of corticosteroids on the perception of dyspnea in asthma.

von Leupoldt A, Kanniess F, Dahme B.

Respir Med. 2007 Jun;101(6):1079-87. Epub 2006 Dec 8. Review.

27.

Association of depression and anxiety with health care use and quality of life in asthma patients.

Kullowatz A, Kanniess F, Dahme B, Magnussen H, Ritz T.

Respir Med. 2007 Mar;101(3):638-44. Epub 2006 Aug 7.

28.

[Pharmacological treatment of COPD and future of anti-inflammatory therapy].

Watz H, Bitter-Suermann S, Kanniess F, Magnussen H.

Med Klin (Munich). 2006 Apr 15;101(4):283-92. Review. German.

PMID:
16607484
29.

Effect of beclomethasone dipropionate (BDP) as extrafine aerosol on bronchoalveolar lavage (BAL) lymphocytes in chronic sarcoidosis.

Ludwig-Sengpiel A, Jaksztat E, Welker L, Zeschnigk T, Kanniess F, Jörres RA, Magnussen H, Kirsten D.

Sarcoidosis Vasc Diffuse Lung Dis. 2005 Oct;22(3):214-21.

PMID:
16315785
30.

Effect of reproterol either alone or combined with disodium cromoglycate on airway responsiveness to methacholine.

Kanniess F, Jörres RA, Magnussen H.

Pulm Pharmacol Ther. 2005;18(5):315-20. Epub 2005 Apr 25.

PMID:
15939309
31.

Validation of the human ozone challenge model as a tool for assessing anti-inflammatory drugs in early development.

Holz O, Tal-Singer R, Kanniess F, Simpson KJ, Gibson A, Vessey RS, Janicki S, Magnussen H, Jörres RA, Richter K.

J Clin Pharmacol. 2005 May;45(5):498-503.

PMID:
15831772
32.

Comparison of the oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in patients with asthma.

Richter K, Kanniess F, Biberger C, Nave R, Magnussen H.

J Clin Pharmacol. 2005 Feb;45(2):146-52.

PMID:
15647406
33.

Direct measurement of BDP and 17-BMP in bronchial and peripheral lung tissue after inhalation of HFA- vs CFC-driven aerosols.

Holz O, Zühlke I, Einhaus M, Welker L, Kanniess F, Branscheid D, Nakashima M, Harrison LI, Jörres RA, Richter K, Magnussen H.

Pulm Pharmacol Ther. 2004;17(4):233-8.

PMID:
15219268
34.

Montelukast attenuates the airway response to hypertonic saline in moderate-to-severe COPD.

Zühlke IE, Kanniess F, Richter K, Nielsen-Gode D, Böhme S, Jörres RA, Magnussen H.

Eur Respir J. 2003 Dec;22(6):926-30.

35.

Reproducibility of forced inspiratory and expiratory volumes after bronchodilation in patients with COPD or asthma.

Taube C, Kanniess F, Grönke L, Richter K, Mücke M, Paasch K, Eichler G, Jörres RA, Magnussen H.

Respir Med. 2003 May;97(5):568-77.

36.

Dose reduction of inhaled corticosteroids under concomitant medication with montelukast in patients with asthma.

Kanniess F, Richter K, Janicki S, Schleiss MB, Jörres RA, Magnussen H.

Eur Respir J. 2002 Nov;20(5):1080-7.

37.

Montelukast versus fluticasone: effects on lung function, airway responsiveness and inflammation in moderate asthma.

Kanniess F, Richter K, Böhme S, Jörres RA, Magnussen H.

Eur Respir J. 2002 Oct;20(4):853-8.

38.

The relationship between airway hyper-responsiveness, markers of inflammation and lung function depends on the duration of the asthmatic disease.

Grönke L, Kanniess F, Holz O, Jörres RA, Magnussen H.

Clin Exp Allergy. 2002 Jan;32(1):57-63.

PMID:
12002738
39.
40.
41.

In patients with chronic bronchitis a four week trial with inhaled steroids does not attenuate airway inflammation.

Loppow D, Schleiss MB, Kanniess F, Taube C, Jörres RA, Magnussen H.

Respir Med. 2001 Feb;95(2):115-21.

42.

[Diagnostics in bronchial asthma].

Magnussen H, Kanniess F.

Internist (Berl). 1999 Aug;40(8):830-6. Review. German. No abstract available.

PMID:
10476480
43.

Assessment of accuracy and applicability of a new electronic peak flow meter and asthma monitor.

Richter K, Kanniess F, Mark B, Jörres RA, Magnussen H.

Eur Respir J. 1998 Aug;12(2):457-62.

Supplemental Content

Loading ...
Support Center